Search Results - "Lugowska, Iwona A."

Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer by Wysocki, Piotr Jan, Lubaś, Maciej Tadeusz, Łobacz, Mateusz, Kalinka, Ewa, Tomczak, Piotr, Kwiatek, Michal, Lugowska, Iwona A., Chraniuk, Dominik, Barde, Prajak J., Vakkalanka, Swaroop V.S., Smakal, Martin

“…154 Background: RP12146 is an orally bioavailable, potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1 and PARP 2. RP1246 demonstrated…”
Get full text

Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors by Wysocki, Piotr Jan, Lubaś, Maciej Tadeusz, Łobacz, Mateusz, Kalinka-Warzocha, Ewa, Tomczak, Piotr, Kwiatek, Michal, Lugowska, Iwona A., Smakal, Martin, Chraniuk, Dominik, Melichar, Bohuslav, Markiewicz-Bialek, Beate, Routhu, Kasi V., Barde, Prajak J., Nair, Ajit

“…3097 Background: RP12146 is an orally bioavailable, potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1 and PARP 2. Pre-clinically, RP1246…”
Get full text

Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial by Schuler, Martin H., Tabernero, Josep, Carranza, Omar, Loriot, Yohann, Pant, Shubham, Arnold, Dirk, Folprecht, Gunnar, Palmer, Daniel H., Prenen, Hans, Zibetti Dal Molin, Graziela, Lugowska, Iwona A., Cervantes, Andres, Sweiti, Hussein, Hammond, Constance, Najmi, Saltanat, Thomas, Shibu, Triantos, Spyros, Xia, Karen, Gutierrez, Martin

“…8515 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved in the US for treatment of…”
Get full text

A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors by Lugowska, Iwona A., Rojas, Carlos, Stathis, Anastasios, Weindler, Susanne, Pal, Abhijit, Castanon Alvarez, Eduardo, Mackiewicz, Jacek, Garrido, Marcelo, Sendur, Mehmet Ali Nahit, Lakhani, Nehal J., Frentzas, Sophia, Dziadziuszko, Rafal, Sacher, Adrian G., Wakuda, Kazushige, Kato, Terufumi, Perets, Ruth, Castillo Fernandez, Omar Orlando, Jemielita, Thomas, Choi, Yewon, Juergens, Rosalyn A.

“…TPS232 Background: Mutations in KRAS are one of the most prevalent oncogene mutations in human cancers, among which KRAS G12C mutations are one of the most…”
Get full text

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results by Meric-Bernstam, Funda, Makker, Vicky, Oaknin, Ana, Oh, Do-Youn, Banerjee, Susana N., Gonzalez Martin, Antonio, Jung, Kyung Hae, Lugowska, Iwona A., Manso, Luis, Manzano, Aránzazu, Melichar, Bohuslav, Siena, Salvatore, Stroyakovskiy, Daniil, Anoka, Chiedozie, Ma, Yan, Puvvada, Soham D., Lee, Jung-Yun

“…LBA3000 Background: T-DXd is an antibody drug conjugate targeting HER2 and is approved in HER2-expressing breast (BC) and gastric (GC) cancers. HER2 expression…”
Get full text

Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations ( FGFRalt ): RAGNAR primary analysis by Pant, Shubham, Schuler, Martin H., Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Reardon, David A., Massard, Christophe, Welsh, Liam, Lugowska, Iwona A., Carranza, Omar, Stuyckens, Kim, Liao, Huimin, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann

“…3121 Background: FGFRalt are present across malignancies at various frequencies and may act as oncogenic drivers across tissue histology. Erda is an oral…”
Get full text

Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial by Pasquali, Sandro, Collini, Paola, Romagosa, Cleofe, Coindre, Jean Michel, Pizzamiglio, Sara, Verderio, Paolo, Barisella, Marta, Palmerini, Emanuela, Quagliuolo, Vittorio, Martin Broto, Javier, Lopez-Pousa, Antonio, Grignani, Giovanni, Blay, Jean-Yves, Lugowska, Iwona A., Fontana, Valeria, Sbaraglia, Marta, Bague, Silvia, De Tos, Paolo, Casali, Paolo G, Gronchi, Alessandro

“…11511 Background: HR after neoadjuvant ChT for high-risk STS has not been prospectively characterized and the prognostic implications remain unclear. This…”
Get full text

A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors by Wang, Judy S., Gutierrez, Martin, Rasco, Drew W., Melero Bermejo, Ignacio, Powderly, John D., Hamilton, Erika P., Millward, Michael, Arance, Ana Maria, Stec, Rafal, Moreno, Victor, Sharma, Manish, Lugowska, Iwona A., Shackleton, Mark J., Frentzas, Sophia, Janik, John Edward, Liu, Tracy, Shapiro, Irina, Whalen, Kerry, Jones, Jeffrey Alan, Spira, Alexander I.

“…2532 Background: MICA and MICB are stress-induced ligands upregulated on the majority of human tumors. Engagement of MICA/B by the activating receptor NKG2D on…”
Get full text

Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort by Luke, Jason J., Sharma, Manish, Chandana, Sreenivasa R, Lugowska, Iwona A., Szczylik, Cezary, Zolnierek, Jakub, Cote, Gregory Michael, Mantia, Charlene, Dziadziuszko, Rafal, Sanborn, Rachel E., Casey, Denise, Long, Lori, Ward, Ashley, Kaminker, Patrick, James, Angela Joubert, Di Pucchio, Tiziana, Cybulska-Stopa, Bożena

“…155 Background: Lorigerlimab (MGD019) is an investigational, bispecific Fc-bearing (IgG4) DART molecule designed to enhance CTLA-4 blockade on dual expressing,…”
Get full text

Prognostic and diagnostic value of Ewing family of tumors (EFTs)-associated fusion transcripts detected in peripheral blood specimens by Przybyl, Joanna, Kosela, Hanna, Wiater, Katarzyna, Ptaszynski, Konrad, Szumera-Cieckiewicz, Anna, Falkowski, Slawomir, Lugowska, Iwona A., Debiec-Rychter, Maria, Siedlecki, Janusz A, Rutkowski, Piotr

“…Abstract only 10538 Background: EFTs are characterized by chromosomal translocations leading to formation of oncogenic EWSR1-FLI1 fusion gene in 85-90% of…”
Get full text